International Nonproprietary Names for Pharmaceutical Substances (INN)

RECOMMENDED International Nonproprietary Names (Rec. INN): List 39

Notice is hereby given that, in accordance with paragraph 7 of the Procedure for the Selection of Recommended International Nonproprietary Names for Pharmaceutical Substances [*Off. Rec. Wld Health Org.*, 1955, **60**, 3 (Resolution EB15.R7); 1969, **173**, 10 (Resolution EB43.R9)], the following names are selected as Recommended International Nonproprietary Names. The inclusion of a name in the lists of Recommended International Nonproprietary Names does not imply any recommendation of the use of the substance in medicine or pharmacy.
Lists of Proposed (1–73) and Recommended (1–35) International Nonproprietary Names can be found in *Cumulative List No 9, 1996.*

Dénominations communes internationales des Substances pharmaceutiques (DCI)

Dénominations communes internationales RECOMMENDÉES (DCI Rec): Liste 39

Il est notifié que, conformément aux dispositions du paragraphe 7 de la Procédure à suivre en vue du choix de Dénominations communes internationales recommandées pour les Substances pharmaceutiques [*Actes off. Org mond. Santé*, 1955, **60**, 3 (résolution EB15.R7); 1969, **173**, 10 (résolution EB43 R9)] les dénominations ci-dessous sont mises à l'étude par l'Organisation mondiale de la Santé en tant que dénominations communes internationales proposées. L'inclusion d'une dénomination dans les listes de DCI proposées n'implique aucune recommandation en vue de l'utilisation de la substance correspondante en médecine ou en pharmacie.
On trouvera d'autres listes de Dénominations communes internationales proposées (1–73) et recommandées (1–35) dans la *Liste récapitulative No 9, 1996.*

Denominaciones Comunes Internacionales para las Sustancias Farmacéuticas (DCI)

Denominaciones Comunes Internacionales RECOMENDADAS (DCI Rec.): Lista 39

De conformidad con lo que dispone el párrafo 7 del Procedimiento de Selección de Denominaciones Comunes Internacionales Recomendadas para las Sustancias Farmacéuticas [*Act. Of. Mund. Salud*, 1955, **60**, 3 (Resolución EB15.R7); 1969, **173**, 10 (Resolución EB43.R9)], se comunica por el presente anuncio que las denominaciones que a continuación se expresan han sido seleccionadas como Denominaciones Comunes Internacionales Recomendadas. La inclusión de una denominación en las listas de las Denominaciones Comunes Recomendadas no supone recomendación alguna en favor del empleo de la sustancia respectiva en medicina o en farmacia
Las listas de Denominaciones Comunes Internacionales Propuestas (1–73) y Recomendadas (1–35) se encuentran reunidas en *Cumulative List No. 9, 1996.*

Discussions have recently taken place between the World Intellectual Property Organization and WHO's Division of Drug Management and Policies regarding the ***protection of International Nonproprietary Names (INN)*** against (mis)use as domain names on INTERNET. These discussions were initiated *inter alia* in view of INN having been registered as domain names on Internet, for purposes not necessarily related to the global identification of a specific pharmaceutical substance to protect the safety of patients. In this regard, there have been several reported cases where an INN-based domain name has been registered on the Internet and then sold to a company which had an interest in avoiding proprietary use of the INN in question.

In order to help ensure that INN are used exclusively for the identification of a specific pharmaceutical substance under one single, globally available name and that no party can claim any proprietary rights to INN, a paragraph relating to INN has been proposed for inclusion in the *Trademark Dispute Resolution, Draft Substantive Guidelines concerning Administrative Domain Name Challenge Panels*. Details are available on:

http://www gtld-mou org/docs/tracps.htm and
http://www wipo.int/eng/internet/domains/index htm

After further consultation, it is suggested that the text of the proposed paragraph, as contained in clause 1 (b) of Annex B of the *Guidelines*, should read as follows[a]:

> *"A name published by the World Health Organization (WHO) in the Cumulative List of International Nonproprietary Names for Pharmaceutical Substances (INN), and updated regularly in WHO Drug Information, pursuant to World Health Assembly (WHA) Resolution 3.11 and subsequent resolutions "*

It is hoped that the inclusion of this paragraph will allow interested parties to challenge the registration of a domain name "if identical or confusingly identical" to an INN, in particular if such a registration has been made in bad faith.

WHO would like to emphasize that its main concern is the safety of patients. In accordance with WHA resolution 3.11 on Non-proprietary Names for Drugs (adopted in May 1950 by the Third World Health Assembly), the Organization is responsible for selecting and promoting the protection of recommended International Nonproprietary Names as a means of identifying pharmaceutical substances under one single, globally available name, in which no party can claim any proprietary rights.

For any further information or comments, please contact the Secretariat of the INN Programme (Division of Drug Management and Policies, World Health Organization, 20 av. Appia, CH-1211 Geneva 27, Fax: +41 22 791 4730, e-mail: koppkubels@who.ch).

[a] Based on the third revised draft of the *Guidelines* dated 16 January 1998.

Latin, English, French, Spanish.

Recommended INN	*Chemical name or description; Molecular formula; Graphic formula*
DCI Recommandée	*Nom chimique ou description; Formule brute; Formule développée*
DCI Recomendada	*Nombre químico o descripción; Fórmula empírica: Fórmula desarrollada*

acidum iocanlidicum (^{123}I)

iocanlidic acid (^{123}I)

15-(*p*-[^{123}I]iodophenyl)pentadecanoic acid

acide iocanlidique (^{123}I)

acide 15-(4-[^{123}I]iodophényl)pentadécanoique

ácido iocanlídico (^{123}I)

ácido 15-(*p*-[^{123}I]iodofenil)pentadecanoico

$C_{21}H_{33}{}^{123}IO_2$



acreozastum

acreozast

N,N'-(2-chloro-5-cyano-*m*-phenylene)bis[glycolamide]diacetate (ester)

acréozast

diacétate de 2,2'-[2-chloro-5-cyano-1,3-phénylènebis(imino)]bis(2-oxoéthyle)

acreozast

éster diacetico de *N,N'*-(2-cloro-5-ciano-*m*-fenilen)bis[glicolamida]

$C_{15}H_{14}ClN_3O_6$



argatrobanum

argatroban

(2*R* 4*R*)-4-methyl-1-[(*S*)-N^2-[[(*RS*)-1 2,3,4-tetrahydro-3-methyl-8-quinolyl]-sulfonyl]arginyl]pipecolic acid

argatroban

acide (2*R*,4*R*)-4-méthyl-1-[(S)-N^2-[[(*RS*)-1,2,3,4-tetrahydro-3-méthyl-8-quinolyl]-sulfonyl]arginyl]pipecolique

argatroban

ácido (2*R*,4*R*)-4-metil-1-[(*S*)-N^2-[[(*RS*)-1,2,3,4-tetrahidro-3-metil-8-quinolil]-sulfonil]arginil]pipecólico

$CH_{23}H_{36}N_6O_5S$



and epimer at C*
et l'épimère en C*
y el epímero al C*

aseripidum

aseripide (2*R*,4*R*)-3-[*N*-[[3-[(*S*)-1-carboxyethyl]phenyl]carbamoyl]glycyl]-2-(*o*-fluorophenyl)-4-thiazolidinecarboxylicacid,4-*tert*-butylester

asérıpide acide (2*S*)-2-[3-[3-[2-[(2*R*,4*R*)-4-[(1,1-diméthyléthoxy)carbonyl]-2-(2-fluorophényl)thiazolidin-3-yl]-2-oxoéthyl]uréido]phényl]propanoique

aseripida (2*R*,4*R*)-3-[*N*-[[3-[(*S*)-1-carboxietil]fenil]carbamoil]glicil]-2-(*o*-fluorofenil)-4-tiazolidinacarboxilato de *terc*-butilo

$C_{26}H_{30}FN_3O_6S$



avoterminum

avotermin transforming growth factor β3 (human), dimer

avotermine facteur de croissance transformant β3 (humain)

avotermina factor β3 de crecimiento transformador(humano), dímero

$C_{1126}H_{1702}N_{296}O_{336}S_{20}$



cedelizumabum

cedelizumab	immunoglobulin G 4 (human-mouse monoclonal OKTcdr4a complementary determining region-grafted γ-chain anti-human CD 4 antigen), disulfide with human-mouse monoclonal OKTcdr4a complementary determining region-grafted κ-chain, dimer
cédélizumab	immunoglobuline G 4 (chaîne γ de l'anticorps monoclonal de souris humanisé OKTcdr4a dirigé contre l'antigène CD 4 humain), dimère du disulfure avec la chaîne κ de l'anticorps monoclonal de souris humanisé OKTcdr4a
cedelizumab	inmunoglobulina G 4 (cadena γ del anticuerpo monoclonal humanizado de ratón OKTcdr4a, dirigido contra el antigeno CD4 humano), dimero del disulfuro con la cadena κ del anticuerpo monoclonal humanizado de ratón OKTcdr4a

ceftizoximum alapivoxilum

ceftizoxime alapivoxil	(+)-(pivaloyloxy)methyl (6R,7R)-7-[2-[2-(L-alanylamino)thiazol-4-yl]glyoxylamido]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate 7^2-(*Z*)-(*O*)-methyloxime)
ceftizoxime alapivoxil	(+)-(6*R*,7*R*)-7-[[2-[2-[[(2*S*)-2-aminopropanoyl]amino]thiazol-4-yl]-2-[(*Z*)-méthoxyimino]acétyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ène-2-carboxylate de [(2,2-diméthylpropanoyl)oxy]méthyle
ceftizoxima alapivoxilo	(6R,7R)-7-[2-[2-(L-alanilamino)tiazolin-4-il]glioxilamido]-8-oxo-5-tia-1-azabiciclo[4.2.0]oct-2-en-2-carboxilato de (+)-pivaloxi)metil, 7^2-(*Z*)-(*O*)-metiloxime)

$C_{22}H_{28}N_6O_8S_2$



celgosivirum

celgosivir	(1*S*,6*S*,7*S*,8*R*,8a*R*)-octahydro-1,7,8-trihydroxy-6-indolizinyl butyrate
celgosivir	butanoate de (1*S*,6*S*,7*S*,8*R* 8a*R*)-1,7,8-trihydroxyoctahydroindolizin-6-yle
celgosivir	butirato de (1*S*,6*S*,7*S* 8*R*,8a*R*)-1,7,8-trihidroxioctahidro 6-indolizinilo

$C_{12}H_2{\cdot}NO_5$



clenoliximabum

clenoliximab — immunoglobulin G 4 (human-Macaca monoclonal CE9γ4PE γ4-chain anti-human antigen CD 4), disulfide with human-Macaca monoclonal CE9γ4PE κ-chain, dimer

clenoliximab — immunoglobuline G 4 (chaîne γ4 de l'anticorps monoclonal chimérique homme-Macaque CE9γ4PE dirigé contre l'antigène CD 4 humain), dimère du disulfure avec la chaîne κ de l'anticorps monoclonal chimérique homme-Macaque CE9γ4PE

clenoliximab — inmunoglobulina G 4 (cadena γ4 del anticuerpo monoclonal quimérico hombre-Macaca CE9γ4PE dirigido contra el antigeno antigen CD 4 humano), dimero del disulfuro con la cadena κ del anticuerpo monoclonal quimérico hombre-Macaca CE9γ4PE

colesevelamum

colesevelam — allylamine polymer with 1-chloro-2,3-epoxypropane, [6-(allylamino)hexyl]= trimethylammonium chloride and *N*-allyldecylamine

colésévélam — copolymère de prop-2-én-1-amine, de dodécan-1-amine et de *N,N,N*-triméthyl-6-(prop-2-énylamino)hexan-1-aminium réticulé à l'aide de 2-(chlorométhyl)oxirane (épichlorhydrine)

colesevelam — copolímero de prop-2-en-1-amino, de dodecan-1-amino y de *N,N,N*-trimetil-6-(prop-2-enilamino)hexan-1-aminio reticulado con 2-(clorometil)oxirano (epiclorhidrina)

deltibantum

deltibant — D-arginyl-L-arginyl-L-prolyl-*trans*-4-hydroxy-L-prolylglycyl-L-phenylalanyl-L-cysteinyl-D-phenylalanyl-L-leucyl-L-arginine, 7,7'-bis(sulfide) with (2*R*,2'*S*)-*N,N* '-hexamethylenebis[2-mercaptosuccinimide]

deltibant — $S^7,S^{7'}$-[hexane-1,6-diylbis[(3*R*,3'*S*)-2,5-dioxopyrrolidin-1,3-diyl)]bis[D-arginyl-L-arginyl-L-prolyl-[(4*R*)-4-hydroxy-L-prolyl]-glycyl-L-phénylalanyl-L-cystéinyl-L-phénylalanyl-L-leucyl-L-arginine]

deltibant — D-arginil-L-arginil-L-prolil-*trans*-4-hidroxi-L-prolilglicil-L-fenilalanil-L-cisteinil-D-fenilalanil-L-leucil-L-arginina, 7,7'-bis(sulfuro) con (2*R*,2'*S*)-*N,N* '-hexametilenbis[2-mercaptosuccinimida]

$C_{128}H_{194}N_{40}O_{28}S_2$



eniluracilum

eniluracil	5-ethynyluracil
eniluracil	5-éthynylpyrimidine-2,4(1*H*,3*H*)-dione
eniluracilo	5-etiniluracilo
	$C_6H_4N_2O_2$



enlimomabum pegolum

enlimomab pegol	immunoglobulin G 2a (mouse monoclonal BI-RR-1 anti-human antigen CD 54), disulfide with mouse monoclonal BI-RR-1 light chain, dimer, reaction product with α-(2-carboxyethyl)-ω- methoxypoly(oxy-1,2-ethanediyl)
enlimomab pégol	*N, N',N'',N''', N''''*-pentakis[α-méthylpoly(oxyéthylène)-ω-(oxypropanoyl)]immunoglobuline G2a (anticorps monoclonal de souris BI-RR-1 dirigé contre l'antigène CD 54 humain), dimère du disulfure avec la chaîne légère de l'anticorps monoclonal de souris BI-RR-1
enlimomab pegol	inmunoglobulina G 2a (anticuerpo monoclonal de ratón BI-RR-1 dirigido contra el antigeno CD 54 humano), dimero del disulfuro con la cadena ligera del anticuerpo de ratón BI-RR-1, producto de reacción con α-(2-carboxietil)-ω-metoxipoli(oxi-1,2-etanodiil)

eplerenonum

eplerenone	9,11α-epoxy-17-hydroxy-3-oxo-17α-pregn-4-ene-7α,21-dicarboxylic acid, γ-lactone, methyl ester
éplérénone	(2'*R*)-9,11α-epoxy-3,5'-dioxo-4',5'-dihydrospiro[androst-4-ène-17, 2'(3*H*)-furane]-7α-carboxylate de méthyle
eplerenona	éster metílico de la γ-lactona del acido 9,11α-epoxi-17-hidroxi-3-oxo-17α-pregn-4-en-7α,21-dicarboxílico
	$C_{24}H_{30}O_6$



felvizumabum

felvizumab — immunoglobulin G 1 (human-mouse monoclonal, γ-chain anti-respiratory syncytial virus), disulfide with human-mouse monoclonal κ -chain, dimer

felvizumab — immunoglobuline G 1 (chaîne γ de l'anticorps monoclonal de souris humanisé dirigé contre le virus syncytial respiratoire), dimère du disulfure avec la chaîne κ de l'anticorps monoclonal de souris humanisé

felvizumab — inmunoglobulina G 1 (cadena γ del anticuerpo monoclonal humanizado de ratón, dirigido contra el virus sincitial respiratorio), dímero del disulfuro con la cadena κ del anticuerpo humanizado de ratón

follitropinum beta

follitropin beta — follicle-stimulating hormone, glycoform β
α-subunit:
chorionic gonadotropin (human α-subunit protein moiety reduced)
β-subunit:
follicle-stimulating hormone (human β-subunit protein moiety reduced)

follitropine bêta — hormone folliculo-stimulante, forme glycosylée β
sous-unité α:
gonadotropine chorionique (partie protéique réduite de la sous-unité α humaine)
sous-unité β:
hormone folliculo-stimulante (partie protéique réduite de la sous-unité β humaine)

folitropina beta — hormona estimulante del folículo, glicoforma β
subunidad α:
gonadotropina coriónica (fracción proteica reducida de la subunidad α humana)
subunidad β.
hormona estimulante del folículo (fracción proteica reducida de la subunidad β)

α. $C_{437}H_{682}N_{122}O_{134}S_{13}$

β: $C_{538}H_{833}N_{145}O_{171}S_{13}$

APDVQDCPEC TLQENPFFSQ PGAPILQCMG CCFSRAYPT
LRSKKTMLVQ KNVTSESTCC VAKSYNRVTV MGGFKVENH
ACHCSTCYYH KS
NSCELTNITI AIEKEECRFC ISINTTWCAG YCYTRDLVY
DPARPKIQKT CTFKELVYET VRVPGCAHHA DSLYTYPVA
QCHCGKCDSD STDCTVRGLG PSYCSFGEMK E

fudosteinum

fudosteine — (-)-3-[(3-hydroxypropyl)thio]-L-alanine

fudostéine — (-)-acide (2*R*)-2-amino-3-[(3-hydroxypropyl)sulfanyl]propanoïque

fudosteína — (-)-3-[(3-hidroxipropil)tio]-L-alanina

$C_6H_{13}NO_3S$



gavestinelum

gavestinel	4,6-dichloro-3-[(*E*)-2-(phenylcarbamoyl)vinyl]indole-2-carboxylic acid
gavestinel	acide 4,6-dichloro-3-[(*E*)-2-(phénylcarbamoyl)éthényl]-1*H*-indole-2-carboxylique
gavestinel	ácido 4,6-dicloro-3-[(E)-2-(fenilcarbamoil)vinil]indol-2-carboxílico

$C_{18}H_{12}Cl_2N_2O_3$



glufosfamidum

glufosfamide	β-D-glucopyranose 1-[*N,N'*-bis(2-chloroethyl)phosphorodiamidate]
glufosfamide	*N,N'*-bis(2-chloroéthyl)phosphorodiamidate de β-D-glucopyranosyle
glufosfamida	1-[*N,N'*-bis(2-cloroetil)fosforodiamidato] de β-D-glucopiranosa

$C_{10}H_{21}Cl_2N_2O_7P$



infliximabum

infliximab	immunoglobulin G (human-mouse monoclonal cA2 heavy chain anti-human tumor necrosis factor), disulfide with human-mouse monoclonal cA2 light chain, dimer
infliximab	immunoglobuline G (chaîne lourde de l'anticorps monoclonal chimérique homme-souris cA2 dirigé contre le facteur de nécrose tumorale humain), dimère du disulfure avec la chaîne légère de l'anticorps monoclonal chimérique homme-souris cA2
infliximab	inmunoglobulina G (cadena pesada del anticuerpo monoclonal quimérico hombre-ratón cA2 dirigido contra el factor de necrosis tumoral humano), dimero del disulfuro con la cadena ligera del anticuerpo monoclonal quimérico hombre-ratón cA2

interferonum alfacon-1

interferon alfacon-1

N-L-methionyl-22-L-arginine-76-L-alanine-78-L-aspartic acid-79-L-glutamic acid-86-L-tyrosine-90-L-tyrosine-156-L-threonine-157-L-asparagine-158-L-leucineinterferon α1 (human lymphoblast reduced)

interféron alfacon-1

N-L-méthionyl-[22-L-arginine-76-L-alanine-78-L-acide aspartique-79-L-acide glutamique-86-L-tyrosine-90-L-tyrosine-156-L-thréonine-157-L-asparagine-158-L-leucine]interféron α1 (lymphoblastique humain réduit)

interferón alfacón-1

N-L-metionil-22-L-arginina-76-L-alanina-78-ácido L-aspártico-79-ácido L-glutámico-86-L-tirosina-90-L-tirosina-156-L-treonina-157-L-asparagina-158-L-leucinainterferón α1(linfoblástico humano reducido)

$C_{870}H_{1366}N_{236}O_{259}S_9$

MCDLPQTHSLG NRRALILLAQ MRRISPFSCL KDRHDFGFPQ
EEFDGNQFQK AQAISVLHEM IQQTFNLFST KDSSAAWDES
LLEKFYTELY QQLNDLEACV IQEVGVEETP LMNVDSILAV
KKYFQRITLY LTEKKYSPCA WEVVRAEIMR SFSLSTNLQE
RLRRKE

lanepitantum

lanepitant

N-[(*R*)-2-indol-3-yl-1-[[*N*-(*o*-methoxybenzyl)acetamido] methyl]ethyl] [1,4'-bipiperidine]-1'-acetamide

lanépitant

N-[(1*R*)-1-[[acétyl(2-méthoxybenzyl)amino]méthyl]-2-(1*H*-indol-3-yl)éthyl]-2-(1,4'-bipipéridin-1'-yl)acétamide

lanepitant

N-[(*R*)-2-indol-3-il-1-[[*N*-(*o*-metoxibencil)acetamido]metil]etil] [1,4'-bipiperidina]-1'-acetamida

$C_{33}H_{45}N_5O_3$



licostinelum

licostinel

6,7-dichloro-1,4-dihydro-5-nitro-2,3-quinoxalinedione

licostinel

6,7-dichloro-5-nitro-1,4-dihydroquinoxaline-2,3-dione

licostinel

6,7-dicloro-1,4-dihidro-5-nitro-2,3-quinoxalinadiona

$C_8H_3Cl_2N_3O_4$



lumefantrinum

lumefantrine (±)-2,7-dichloro-9-[(*Z*)-*p*-chlorobenzylidene]-α[(dibutylamino)methyl]fluorene-4-methanol

luméfantrine (1*RS*)-2-(dibutylamino)-**1**-[(*Z*)-2,7-dichloro-9-(4-chlorobenzylidène)-9*H*-fluorén-4-yl]éthanol

lumefantrina (±)-2,7-dicloro-9-[(*Z*)-*p*-clorobencilideno]-α[(dibutilamino)metil]fluoreno-4-metanol

$C_{30}H_{32}Cl_3NO$



and enantiomer
et énantiomère
y enantiomero

milacainidum

milacainide (-)-(*R*)-2-amino-*N*-[3-(3-pyridyl)propyl]-2',6'-propionoxylidide

milacaïnide (-)-(*R*)-2-amino-*N*-(2 6-diméthylphényl)-*N*-[3-(pyridin-3-yl)propyl]propanamide

milacainida (-)-(*R*)-2-amino-*N*-[3-(3-piridil)propil]-2',6'-propionoxilidida

$C_{19}H_{25}N_3O$



mivobulinum

mivobulin — ethyl (*S*)-5-amino-1,2-dihydro-2-methyl-3-phenylpyrido[3,4-*b*]pyrazine-7-carbamate

mivobuline — [(2*S*)-5-amino-2-méthyl-3-phényl-1,2-dihydropyrido[3,4-*b*]pyrazin-7-yl]carbamate d'éthyle

mivobulina — (*S*)-5-amino-1,2-dihidro-2-metil-3-fenilpirido [3,4-*b*]pirazina-7-carbamato de etilo

$C_{17}H_{19}N_5O_2$



nateglinidum

nateglinide — (-)-*N*-[(*trans*-4-isopropylcyclohexyl)carbonyl]-D-phenylalanine

natéglinide — (-)-acide (2*R*)-2-[[[*trans*-4-(1-méthyléthyl)cyclohexyl]carbonyl]amino]-3-phénylpropanoïque

nateglinida — (-)-*N*-[(*trans*-4-isopropilciclohexil)carbonil]-D-fenilalanina

$C_{19}H_{27}NO_3$



nonacogum alfa

nonacog alfa — blood-coagulation factor IX (human), glycoform α

nonacog alfa — facteur IX de coagulation sanguine humain, glycoforme α

nonacog alfa — factor IX (humano) de la coagulación sanguínea, forma glucosilada α

oberadilolum

oberadilol — (±)-4-chloro-2-[3-[[1,1-dimethyl-2-[*p*-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)anilino]ethyl]amino]-2-hydroxypropoxy]benzonitrile

obéradilol — 4-chloro-2-[3-[[1,1-diméthyl-2-[[4-(4-méthyl-6-oxo-1,4,5,6-tétrahydropyridazin-3-yl)phényl]amino]éthyl]amino]-2-hydroxypropoxy]benzonitrile

oberadilol — (±)-4-cloro-2-[3-[[1,1-dimetil-2-[*p*-(1,4,5,6-tetrahidro-4-metil-6-oxo-3-piridazinil)anilino]etil]amino]-2-hidroxipropoxi]benzonitrilo

$C_{25}H_{30}ClN_5O_3$



opanixilum

opanixil	4-amino-2-(4,4-dimethyl-2-oxo-1-imidazolidinyl)-*N*-ethyl-α,α,α-trifluoro-5-pyrimidinecarboxy-*m*-toluidide
opanixil	4-amino-2-(4,4-diméthyl-2-oxoimidazolidin-1-yl)-*N*-éthyl-*N*-[3-(trifluorométhyl)phényl]pyrimidin-5-carboxamide
opanixilo	4-amino-2-(4,4-dimetil-2-oxo-1-imidazolidinil)-*N*-etil-α,α,α-trifluoro-5-pirimidinacarboxi-*m*-toluidida

$C_{19}H_{21}F_3N_6O_2$



oraziponum

orazipone	3-[*p*-(methylsulfonyl)benzylidene]-2 4-pentanedione
orazipone	3-[4-(méthylsulfonyl)benzylidène]pentane-2,4-dione
orazipona	3-[*p*-(metilsulfonil)bencilíden]-2,4-pentanodiona

$C_{13}H_{14}O_4S$



pegmusirudinum

pegmusirudin

L-valyl-L-valyl-L-tyrosyl-L-threonyl- L-α-aspartyl-L-cysteinyl-L-threonyl-L-α-glutamyl-L-serylglycyl-L-glutaminyl-L-asparaginyl-L-leucyl-L-cysteinyl-L-leucyl-L-cysteinyl-L-α-glutamylglycyl-L-seryl-L-asparaginyl-L-valyl-L-cysteinylglycyl-L-glutamylglycyl- L-asparaginyl-N^6-carboxy-L-lysyl-L-cysteinyl-L-isoleucyl-L-leucylglycyl-L-seryl-N^6-carboxy-L-lysylglycyl-L-α-glutamyl-L-arginyl-L-asparaginyl-L-glutaminyl-L-cysteinyl-L-valyl-L-threonylglycyl-L-α-glutamylglycyl-L-threonyl-L-prolyl-L-arginyl-L-prolyl-L-glutaminyl-L-seryl-L-histidyl-L-asparaginyl-L-α-aspartylglycyl-L-α-aspartyl-L-phenylalanyl-L-α-glutamyl-L-α-glutamyl-L-isoleucyl-L-prolyl-L-α-glutamyl-L-α-glutamyl-L-tyrosyl-L-leucyl-L-glutamine cyclic (6 →14), (16 →28), (22→ 39)-tris(disulfide), 27,33-diester with polyethylene glycol monoethyl ether

pegmusirudine

$N^{6\,27}$,$N^{6\,33}$-bis[α-méthylpoly(oxyéthylène)-ω-(oxycarbonyl)]-[33-L-lysine-36-L-arginine-47-L-arginine]-O^{63}-désulfohirudine (*hirudo medicinalis*)

pegmusirudina

L-valil-L-valil-L-tirosil-L-treonil- L-α-aspartil-L-cisteinil-L-treonil-L-α-glutamil-L-seriglicil-L-glutaminil-L-asparaginil-L-leucil-L-cisteinil-L-leucil-L-cisteinil-L-α-glutamilglicil-L-seril-L-asparaginil-L-valil-L-cisteinilglicil-L-glutamilglicil-L-asparaginil-N^6-carboxi-L-lisil-L-cisteinil-L-isoleucil-L-leucilglicil-L-seril-N^6-carboxi- L-lisilglicil-L-α-glutamil-L-arginil-L-asparaginil-L-glutaminil-L-cisteinil-L-valil-L-treonilglicil-L-α-glutamilglicil-L-treonil-L-prolil-L-arginil-L-prolil-L-glutaminil-L-seril-L-histidil-L-asparaginil-L-α-aspartilglicil-L-α-aspartil-L-fenilalanil-L-α-glutamil-L-α-glutamil-L-isoleucil-L-prolil-L-α-glutamil-L-α-glutamil-L-tirosil-L-leucil-L-glutamine tris(disulfuro) cíclico (6 →14), (16 →28), (22→ 39), 27,33-diester con polietilen glicol monoetil eter

$(C_2H_4O)_n\,(C_2H_4O)_n\,C_{302}H_{451}N_{85}O_{112}S_6$



pifonakinum

pifonakin

36-L-aspartic acid-141-L-serineinterleukin 1α (human clone p10A)

pifonakine

[36-acide L-aspartique-141-L-sérine]interleukine 1α (clone humain p10A)

pifonakina

36-L-ácido aspártico-141-L-serinainterleuquina 1α (clon humano p10A)

SAPFSFLSNV KYNFMRIIKY EFILNDALNQ SIIRADDQYL
TAAALHNLDE AVKFDMGAYK SSKDDAKITV ILRISKTQLY
VTAQDEDQPV LLKEMPEIPK TITGSETNLL FFWETHGTKN
YFTSVAHPNL FIATKQDYWV SLAGGPPSIT DFQILENQA

pleconarilum

pleconaril — 3-[4-[3-(3-methyl-5-isoxazolyl)propoxy]-3,5-xylyl]-5-(trifluoromethyl)-1,2,4-oxadizole

pléconaril — 3-[3,5-diméthyl-4-[3-(3-méthylisoxazol-5-yl)propoxy]phényl]-5-(trifluorométhyl)-1,2,4-oxadiazole

pleconarilo — 3-[4-[3-(3-metil-5-isoxazolil)propoxi]-3,5-xilil]-5-(trifluorometil)-1,2,4-oxadizol

$C_{18}H_{16}F_3N_3O_3$



pralmorelinum

pralmorelin — D-alanyl-3-(2-naphthyl)-D-alanyl-L-alanyl-L-tryptophyl-D-phenylalanyl-L-lysinamide

pralmoréline — D-alanyl-[3-(naphtalén-2-yl)-D-alanyl]-L-alanyl-L-tryptophyl-D-phénylalanyl-L-lysinamide

pralmorelina — D-alanil-3-(2-naftil)-D-alanil-L-alanil-L-triptofil-D-fenilalanil-L-lisinamida

$C_{45}H_{55}N_9O_6$



promazinum

promazine — 10-(3-dimethylaminopropyl)phenotniazine

promazine — (diméthylamino-3-propyl)-10-aza-1-phénothiazine

promazina — 10-(3-dimetilaminopropil)fenotiazina

$C_{17}H_{20}N_2S$



rituximabum

rituximab — immunoglobulin G 1 (human-mouse monoclonal IDEC-C2B8 γ1-chain anti-human antigen CD 20), disulfide with human-mouse monoclonal IDEC-C2B8 κ-chain, dimer

rituximab — immunoglobuline G1 (chaîne γ1 de l'anticorps monoclonal chimérique homme-souris IDEC-C2B8 dirigé contre l'antigène CD20 humain), dimère du disulfure avec la chaîne κ de l'anticorps monoclonal chimérique homme-souris IDEC-C2B8

rituximab — inmunoglobulina G 1 (cadena γ1 del anticuerpo monoclonal quimérico hombre-ratón IDEC-C2B8 dirigido contra el antigeno CD 20 humano), dimero del disulfuro con la cadena κ del anticuerpo monoclonal quimerico hombre-raton IDEC-C2B8

rivastigminum

rivastigmine — (-)-*m*-[(*S*)-1-(dimethylamino)ethyl]phenyl ethylmethylcarbamate

rivastigmine — (-)-éthylméthylcarbamate de 3-[(1*S*)-1-(diméthylamino)éthyl]phényle

rivastigmina — etilmetilcarbamato de (-)-*m*-[(*S*)-1-(dimetilamino)etil]fenilo

$C_{14}H_{22}N_2O_2$



roflumilastum

roflumilast — 3-(cyclopropylmethoxy)-*N*-(3,5-dichloro-4-pyridyl)-4-(difluoromethoxy)-benzamide

roflumilast — 3-(cyclopropylméthoxy)-*N*-(3,5-dichloropyridin-4-yl)-4-(difluorométhoxy)-benzamide

roflumilast — 3-(ciclopropilmetoxi)-*N*-(3,5-dicloro-4-piridil)-4-(difluorometoxi)benzamida

$C_{17}H_{14}Cl_2F_2N_2O_3$



roxifibanum

roxifiban — (2*S*)-3-[2-[(5*R*)-3-(*p*-amidinophenyl)-2-isoxazolin-5-yl] acetamido]-2-(carboxyamino)propionic acid, 2-butyl methyl ester

roxifiban — (2*S*)-3-[[2-[(5*R*)-3-(4-carbamimidoylphényl)-4,5-dihydroisoxazol-5-yl]acétyl]amino]-2-[(butoxycarbonyl)amino]propanoate de méthyle

roxifibán — 2-butil metil éster del ácido (2*S*)-3-[2-[(5*R*)-3-(*p*-amidinofenil)-2-isoxazolin-5-il]acetamido]-2-(carboxiamino)propiónico

$C_{21}H_{29}N_5O_6$



sevelamerum

sevelamer — allylamine polymer with 1-chloro-2,3-epoxypropane

sévélamer — copolymère de prop-2-én-1-amine et de 1,3-bis(prop-2-énylamino)propan-2-ol

sevelámero — copolímero de prop-2-en-1-amino y de 1,3-bis(prop-2-enilamino)propan-2-ol

sibrafibanum

sibrafiban — ethyl (*Z*)-[[1-[*N*-[(*p*-hydroxyamidino)benzoyl]-L-alanyl]-4-piperidyl]oxy] acetate

sibrafiban — [[1-[(2*S*)-2-[[4-[(*Z*)-amino(hydroxyimino)méthyl]benzoyl]amino]propanoyl]-piperidin-4-yl]oxy]acétate d'éthyle

sibrafibán — (*Z*)-[[1-[*N*-[(*p*-hidroxiamidino)benzoil]-L-alanil]-4-piperidil]oxi] acetato de etilo

$C_{20}H_{28}N_4O_6$



tazomelinum
tazomeline

3-[4-(hexylthio)-1,2,5-thiadiazol-3-yl]1,2,5,6-tetrahydro-1-methylpyridine

tazoméline

3-[4-(hexylsulfanyl)-1,2 5-thiadiazol-3-yl]-1-méthyl-1,2,5,6-tétrahydropyridine

tazomelina

3-[4-(hexiltio)-1,2,5-tiadiazol-3-il]1,2,5,6-tetrahidro-1-metilpiridina

$C_{14}H_{23}N_3S_2$



terestigminum
terestigmine

(4a*S*,9a*S*)-2,3,4,4a,9,9a-hexahydro-2,4a,9-trimethyl-1,2-oxazino[6,5-*b*]indol-6-yl heptylcarbamate

térestigmine

heptylcarbamate de (4a*S*,9a*S*)-2,4a,9-triméthyl-2,3,4,4a,9,9a-hexahydro-1,2-oxazino[6,5-*b*]indol-6-yle

terestigmina

heptilcarbamato de (4a*S*,9a*S*)-2,3,4,4a,9,9a-hexahidro-2,4a,9-trimetil-1,2-oxazino[6,5-*b*]indol-6-ilo

$C_{21}H_{33}N_3O_3$



trecovirsenum

trecovirsen

P-thiothymidylyl-(5'→3')-2'-deoxy-*P*-thiocytidylyl-(5'→3')-*P*-thiothymidylyl-(5'→3')-*P*-thiothymidylyl-(5'→3')-2'-deoxy-P-thiocytidylyl-(5'→3')-2'-deoxy-*P*-thiocytidylyl-(5'→3')-*P*-thiothymidylyl-(5'→3')-2'-deoxy-*P*-thiocytidylyl-(5'→3')-*P*-thiothymidylyl-(5'→3')-2'-deoxy-*P*-thiocytidylyl-(5'→3')-*P*-thiothymidylyl-(5'→3')-2'-deoxy-*P*-thiocytidylyl-(5'→3')-*P*-thiothymidylyl-(5'→3')-2'-deoxy-*P*-thioadenylyl-(5'→3')-2'-deoxy-*P*-thiocytidylyl-(5'→3')-2'-deoxy-*P*-thiocytidylyl-(5'→3')-2'-deoxy-*P*-thiocytidylyl-(5'→3')-2'-deoxy-*P*-thioadenylyl-(5'→3')-2'-deoxy-*P*-thiocytidylyl-(5'→3')-2'-deoxy-*P*-thioguanylyl-(5'→3')-2'-deoxy-*P*-thiocytidylyl-(5'→3')-*P*-thiothymidylyl-(5'→3')-2'-deoxy-*P*-thiocytidylyl-(5'→3')-*P*-thiothymidylyl-(5'→3')-2'-deoxycytosine

trécovirsen

P-thiothymidylyl-(5'→3')-2'-désoxy-*P*-thiocytidylyl-(5'→3')-*P*-thiothymidylyl-(5'→3')-*P*-thiothymidylyl-(5'→3')-2'-désoxy-*P*-thiocytidylyl-(5'→3')-2'-désoxy-*P*-thiocytidylyl-(5'→3')-*P*-thiothymidylyl-(5'→3')-2'-désoxy-*P*-thiocytidylyl-(5'→3')-*P*-thiothymidylyl-(5'→3')-2'-désoxy-*P*-thiocytidylyl-(5'→3')-*P*-thiothymidylyl-(5'→3')-2'-désoxy-*P*-thioadénylyl-(5'→3')-2'-désoxy-*P*-thiocytidylyl-(5'→3')-2'-désoxy-*P*-thiocytidylyl-(5'→3')-2'-désoxy-*P*-thiocytidylyl-(5'→3')-2'-désoxy-*P*-thioadénylyl-(5'→3')-2'-désoxy-*P*-thiocytidylyl-(5'→3')-2'-désoxy-*P*-thioguanylyl-(5'→3')-2'-désoxy-*P*-thiocytidylyl-(5'→3')-*P*-thiothymidylyl-(5'→3')-2'-désoxy-*P*-thiocytidylyl-(5'→3')-*P*-thiothymidylyl-(5'→3')-2'-désoxycytosine

trecovirseno

P-tiotimidilil-(5'→3')-2'-desoxi-*P*-tiocitidilil-(5'→3')-*P*-tiotimidilil-(5'→3')-*P*-tiotimidilil-(5'→3')-2'-desoxi-*P*-tiocitidilil-(5'→3')-2'-desoxi-*P*-tiocitidilil-(5'→3')-*P*-tiotimidilil-(5'→3')-2'-desoxi-*P*-tiocitidilil-(5'→3')-*P*-tiotimidilil-(5'→3')-2'-desoxi-*P*-tiocitidilil-(5'→3')-*P*-tiotimidilil-(5'→3')-2'-desoxi-*P*-tioadenilil-(5'→3')-2'-desoxi-*P*-tiocitidilil-(5'→3')-2'-desoxi-*P*-tiocitidilil-(5'→3')-2'-desoxi-*P*-tioadenilil-(5'→3')-2'-desoxi-*P*-tiocitidilil-(5'→3')-2'-desoxi-*P*-tioguanilil-(5'→3')-2'-desoxi-*P*-tiocitidilil-(5'→3')-*P*-tiotimidilil-(5'→3')-2'-desoxi-*P*-tiocitidilil-(5'→3')-*P*-tiotimidilil-(5'→3')-2'-desoxicitosina

$C_{237}H_{310}N_{72}O_{131}P_{24}S_{24}$

upenazimum

upenazime

3,3'-(tetramethylenedimino)bis[3-methyl-2-butanone] dioxime

upénazime

3,3'-(butane-1,4-diyldimino)bis(3-méthylbutan-2-one) (*E*,*E*)-dioxime

upenazima

3,3'-(tetrametilendimino)bis[3-metil-2-butanona] dioxima

$C_{14}H_{30}N_4O_2$



urokinasum alfa

urokinase alfa — urokinase (enzyme-activating) (human clone pA3/pD2/pF1 high-molecular-weight isoenzyme protein moiety)

urokinase alfa — activateur du plasminogène (partie protéique de l'isoenzyme de masse moléculaire élevée fournie par le clone humain pA3/pD2/pF1)

urokinasa alfa — uroquinasa, activador del plasminógeno (fracción proteica de la isoenzima de masa molecular elevada producida por el clon humano pA3/pD2/pF1)

vatanidipinum

vatanidipine — (±)-*p*-[4-(diphenylmethyl)-1-piperazinyl]phenethyl methyl 1,4-dihydro-2,6-dimethyl-4-(*m*-nitrophenyl)-3,5-pyridinedicarboxylate

vatanidipine — (4*RS*)-2,6-diméthyl-4-(3-nitrophényl)-1,4-dihydropyridine-3,5-dicarboxylate de 2-[4-[4-(diphénylméthyl)pipérazin-1-yl]phényl]éthyle et de méthyle

vatanidipino — 1,4-dihidro-2,6-dimetil-4-(*m*-nitrofenil)-3,5-piridinadicarboxilato de (±)-*p*-[4-(difenilmetil)-1-piperazinil]fenetilo y metilo

$C_{41}H_{42}N_4O_6$



and enantiomer
et l'énantiomère
y enantiómero

xylazinum

xylazine — 5,6-dihydro-2-(2,6-xylidino)-4*H*-1,3-thiazine

xylazine — 2-(2,6-xylidino)-5,6-dihydro-4*H*-1,3-thiazine

xylazina — 2-(2,6-xilidino)-5,6-dihidro-4*H*-1,3-tiazina

$C_{12}H_{16}N_2S$



AMENDMENTS TO PREVIOUS LISTS
MODIFICATIONS APPORTÉES AUX LISTES ANTÉRIEURES
MODIFICACIONES A LAS LISTAS ANTERIORES

Recommended International Nonproprietary Names (Rec. INN): List 31
(WHO Drug Information, Vol. 5, No. 3, 1991)

p. 4 **dalteparinum natricum**
dalteparin sodium

replace the definition by the following.
Sodium salt of a low molecular mass heparin that is obtained by nitrous acid depolymerization of heparin from porcine intestinal mucosa; the majority of the components have a 2-*O*-sulfo-α-L-idopyranosuronic acid structure at the non-reducing end and a 6-*O*-sulfo-2,5-anhydro-D-mannitol structure at the reducing end of their chain, the mass-average molecular mass ranges between 5600 and 6400 with a characteristic value of about 6000; the degree of sulfatation is 2.0 to 2.5 per disaccharidic unit

p. 10 **parnaparinum natricum**
parnaparin sodium

replace the definition by the following.
Sodium salt of a low molecular mass heparin that is obtained by radical-catalyzed depolymerization, with hydrogen peroxide and with a cupric salt, of heparin from bovine or pork intestinal mucosa; the majority of the components have a 2-*O*-sulfo-α-L-idopyranosuronic acid structure at the non-reducing end and a 2-*N*,6-*O*-disulfo-D-glucosamine structure at the reducing end of their chain; the mass-average molecular mass ranges between 4000 and 6000 with a characteristic value of about 5000, the degree of sulfatation is 2.0 to 2.6 per disaccharidic unit

p. 11 **reviparinum natricum**
reviparin sodium

replace the definition by the following
Sodium salt of a low molecular mass heparin that is obtained by nitrous acid depolymerization of heparin from porcine intestinal mucosa, the majority of the components have a 2-*O*-sulfo-α-L-idopyranosuronic acid structure at the non-reducing end and a 6-*O*-sulfo-2,5-anhydro-D-mannitol structure at the reducing end of their chain: the mass-average molecular mass ranges between 3150 and 5150, with a characteristic value of about 4150; the degree of sulfatation is about 2.1 per disaccharidic unit.

p 16 **enoxaparinum natricum**

enoxaparin sodium

replace the definition by the following:

Sodium salt of a low molecular mass heparin that is obtained by alkaline depolymerization of the benzyl ester derivative of heparin from porcine intestinal mucosa, the majority of the components have a 2-*O*-sulfo-4-desoxy-4-α-L-*threo*-hex-4-enopyranosuronic acid structure at the non-reducing end of their chain, the mass-average molecular mass ranges between 3500 and 5500 with a characteristic value of about 4500, the degree of sulfatation is about 2 per disaccharidic unit.

Recommended International Nonproprietary Names (Rec. INN): List 32
(WHO Drug Information, Vol. 6, No. 3, 1992)

p 10 **tinzaparinum natricum**

tinzaparin sodium

replace the definition by the following:

Sodium salt of a low molecular mass heparin that is obtained by controlled enzymatic depolymerization of heparin from porcine intestinal mucosa using heparinase from *Flavobacterium heparinum*, the majority of the components have a 2-*O*-sulfo-4-desoxy-4-α-L-*threo*-hex-4-enopyranosuronic acid structure at the non-reducing end and a 2-*N*,6-*O*-disulfo-D-glucosamine structure at the reducing end of their chain; the mass-average molecular mass ranges between 5500 and 7500 with a characteristic value of about 6500; the degree of sulfatation is 1.8 to 2.5 per disaccharidic unit

Recommended International Nonproprietary Names (Rec. INN): List 35
Dénominations communes internationales recommendées (DCI Rec.): Liste 35
Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 35
(WHO Drug Information, Vol. 9, No. 3, 1995)

p. 14 **itamelinum**

itameline

replace the chemical name by the following:

(E)-p-chlorophenyl 3-formyl-5,6-dihydro-1(2*H*)-pyridinecarboxylate, *O*-methyloxime

itamelina

sustituyase el nombre quimico por lo siguiente:

3-formil-5,6-dihidro-1(2*H*)-piridinacarboxilato de *(E)-p*-clorofenilo, *O*-metiloxima

p 11 **eptacogum alfa (activatum)**

eptacog alfa (activated)
eptacog alfa (activé)
eptacog alfa (activado)

replace the molecular formula by the following:
remplacer la formule brute par:
sustituyase la fórmula empírica por:

$C_{1982}H_{3054}N_{560}O_{618}S_{28}$

Recommended International Nonproprietary Names (Rec. INN): List 36

Dénominations communes internationales recommendées (DCI Rec.): Liste 36

Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 36

(WHO Drug Information, Vol. 10, No. 3, 1996)

p. 148 **igovomabum**

igovomab	*replace the description by the following:* immunoglobulin G 1 (mouse monoclonal OC125 $F(ab')_2$ $F(ab')_2$fragment anti-human ovarian cancer antigen CA 125), disulfide with mouse monoclonal OC125 $F(ab')_2$ light chain
igovomab	*remplacer la description par la suivante:* fragment $F(ab')_2$ de l'anticorps monoclonal OC 125 $F(ab')_2$ dirigé contre l'antigène CA 125 associé à certaines tumeurs ovariennes
igovomab	*sustituyase la descripción por la siguiente:* fragmento $F(ab')_2$ del anticuerpo monoclonal OC 125 $F(ab')_2$ anti-antígeno CA 125 asociado a ciertos tumores ováricos

p. 160 **thymalfasinum**

thymalfasin	*replace the molecular formula by the following:*
thymalfasine	*remplacer la formule brute par la suivante:*
timalfasina	*sustituyase la fórmula empínca por:*

$C_{129}H_{215}N_{33}O_{55}$

p. 154 **palonosetronum**

palonosetron	*replace the chemical name and the molecular formula by the following.* (3aS)-2,3,3a,4,5,6-hexahydro-2-[(3*S*)-3-quinuclidinyl]-1*H*-benz[*de*]isoquinolin-1-one
palonosétron	*remplacer le nom chimique et la formule brute par :* (3a*S*)-2-[(3*S*)-1-azabicyclo[2 2.2]oct-3-yl]-2.3,3a,4,5,6-hexahydro-1*H*-benzo[*de*]isoquinolein-1-one
palonosetrón	*sustituyanse el nombre químico y la fórmula empírica por* (3aS)-2,3,3a,4,5,6-tetrahidro-2-[(3*S*)-3-quinuclidinil]-1*H*-benz[*de*]isoquinolin-1-ona

$C_{19}H_{24}N_2O$

Dénominations communes internationales recommendées (DCI Rec.): Liste 31
(Informations pharmaceutiques OMS, Vol. 5, No. 3, 1991)

p. 5 **dalteparinum natricum**
daltéparine sodique

remplacer la descnption par
Sel sodique d'une héparine de basse masse moléculaire obtenue par depolymerisation, au moyen d'acide nitreux, d'heparine de muqueuse intestinale de porc, la majorité des composants de la daltéparine sodique possèdent une structure acide 2-*O*-sulfo-α-L-idopyranosuronique à l'extrémité non reductrice de leur chaîne et une structure 6-*O*-sulfo-2,5-anhydro-D-mannitol à l'extrémité réductrice de leur chaîne, la masse moleculaire relative moyenne est de 5600 à 6400, avec une valeur caractéristique de 6000 environ; le degré de sulfatation est de 2 0 à 2 5 par unité disaccharidique.

p 10 **parnaparinum natricum**
parnaparine sodique

remplacer la description par
Sel sodique d'une héparine de basse masse moléculaire obtenue par dépolymerisation, à catalyse radicalaire , au moyen de peroxyde d'hydrogene et d'un sel de cuivre, d'héparine de muqueuse intestinale de boeuf ou de porc, la majorité des composants de la parnaparine sodique possèdent une structure acide 2-*O*-sulfo-α-L-idopyranosuronique à l'extrémité non réductrice de leur chaîne et une structure 2*N*,6-*N*,6-*O*-disulfo-D-glucosamine à l'extremité réductrice de leur chaîne; la masse moléculaire relative moyenne est de 4000 a 6000, avec une valeur caractéristique de 5000 environ, le degré de sulfatation est de 2.0 à 2.6 par unité disaccharidique

p 17 **enoxaparinum natricum**
énoxaparine sodique

remplacer la description par
Sel sodique d'une héparine de basse masse moléculaire obtenue par dépolymerisation alcaline de l'ester benzylique d'héparine de muqueuse intestinale de porc; la majorité des composants de l'enoxaparine sodique possèdent une structure acide 2-*O*-sulfo-4-désoxy-4-α-L-*thréo*-hex-4-énopyranosuronique à l'extrémité non réductrice de leur chaîne, la masse moléculaire relative moyenne est de 3500 à 5500, avec une valeur caractéristiquede 4500 environ;le degré de sulfatation est de 2 par unité disaccharidique.

p. 12 **reviparinum natricum**
réviparine sodique

remplacer la description suivante
Sel sodique d'une héparine de basse masse moléculaire obtenue par dépolymerisation, au moyen d'acide nitreux, d'héparine de muqueuse intestinale de porc; la majorité des composants de la réviparine sodique possèdent une structure acide 2-*O*-sulfo-α-L-idopyranosuronique à l'extrémité non réductrice de leur chaîne et une structure 6-*O*-sulfo-2,5-anhydro-D-mannitol à l'extrémité réductrice de leur chaîne, la masse moléculaire relative moyenne est de 3150 à 5150, avec une valeur caractéristique de 4150 environ, le degré de sulfatation est 2 1 environ par unité disaccharidique

Dénominations communes internationales recommendées (DCI Rec.): Liste 32
(Informations pharmaceutiques OMS, Vol. 6, No. 3, 1992)

p. 10 **tinzaparinum natricum**
tinzaparine sodique

remplacer la description par:
Sel sodique d'une héparine de basse masse moléculaire obtenue par dépolymerisation enzymatique controlée, au moyen de l'héparinase de *Flavobacterium heparinum*, d'héparine de muqueuse intestinale de porc; la majorité des composants de la tinzaparine sodique possèdent une structure acide 2-*O*-sulfo-4-désoxy-4-α-L-*thréo*-hex-4-énopyranosuronique à l'extrémité non réductrice de leur chaîne et une structure 6-*N*,6-*O*-disulfo-D-glucosamine à l'extrémité réductrice de leur chaîne; la masse moléculaire relative moyenne est de 5500 à 7500, avec une valeur caractéristique de 6500 environ: le degré de sulfatation est de 1.8 à 2.5 par unité disaccharidique

Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 31
(Información Farmacéutica, OMS, Vol. 5, No. 3, 1991)

p. 4 **dalteparinum natricum**
dalteparina sódica

sustituyase la descripción por la siguiente:
Sal sódica de una heparina de baja masa molecular obtenida por despolimerización con ácido nitroso de la heparina de la mucosa intestinal de cerdo, la mayoria de los componentes tienen una estructura de ácido 2-*O*-sulfo-α-L-idopiranosurónico en el extremo no reductor y una estructura de 6-*O*-sulfo-2,5-anhidro-D-mannitol en el extremo reductor de la cadena, la masa molecular relativa media es de 5600 a 6400, con un valor caracteristico de 6000 aproximadamente; el grado de sulfatacion es de 2 0 a 2 5 por unidad de disacárido.

p 10 **parnaparinum natricum**
parnaparina sódica

sustituyase la descripción por la siguiente·
Sal sódica de una heparina de baja masa molecular obtenida por despolimerización con peróxido de hidrógeno y un sal de cobre de la heparina de la mucosa intestinal de buey o de cerdo, la mayoria de los componentes tienen una estructura de ácido 2-*O*-sulfo-α-L-idopiranosuronico en el extremo no reductor y una estructura de 6-*O* -6-*N*-disulfo-D-glucosamina en el extremo reductor de la cadena, la masa molecular relativa media es de 4000 a 6000, con un valor caracteristico de 5000 aproximadamente· el grado de sulfatación es de 2.0 a 2 6 por unidad de disacarido.

p. 16 **enoxaparinnum natricum**
enoxaparina sódica

sustituyase la descripción por la siguiente
Sal sódica de una heparina de baja masa molecular obtenida por despolimerización alcalina del éster bencílico de la heparina de la mucosa intestinal de cerdo, la mayoría de los componentes tienen una estructura de ácido 2-*O*-sulfo-4-desoxi-4-α-L-*treo*-hex-4-enopiranosurónico en el extremo no reductor en el extremo reductor de la cadena; la masa molecular relativa media es de 3500 a 5500, con un valor característico de 4500 aproximadamente, el grado de sulfatación es de 2 por unidad de disacárido.

p 11 **reviparinum natricum**
reviparina sódica

sustituyase la descripción por la siguiente
Sal sódica de una heparina de baja masa molecular obtenida por despolimerisación con ácido nítrico de la heparina de la mucosa intestinal del cerdo; la mayoría de los compuestos tienen una estructura de ácido 2-O-sulfo-α-L-idopiranosurónico en el extremo no reductor y una estructura de 6-*O*-sulfo-2,5-anhidro-D-manitol en el extremo reductor de la cadena, la masa molecular relativa media está entre 3150 y 5150, un valor característico de 4150 aproximadamente, el grado de sulfatación es de 2.1 por unidad de disacárido.

Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 32
(Información Farmacéutica, OMS, Vol. 6, No. 3, 1992)

p. 9 **tinzaparinum natricum**
tinzaparina sódica

sustituyase la descripción por la siguiente
Sal sódica de una heparina de baja masa molecular obtenida por despolimerización enzimatica controlada con heparinasa de *Flavobacterium heparinum* de la heparina de la mucosa intestinal de cerdo; la mayoría de los componentes tienen una estructura de ácido 2-*O*-sulfo-4-desoxy-4-α-L-*treo*-hex-4-enopiranosurónico en el extremo no reductor y una estructura de 6-*O*-6-*N*-disulfo-D-glucosamina en el extremo reductor de la cadena, la masa molecular relativa media es de 5500 a 7500, con un valor característico de 6500 aproximadamente; el grado de sulfatación es de 1.8 a 2 5 por unidad de disacárido

Proposed International Nonproprietary Names (Rec. INN): List 35
Dénominations communes internationales proposées (DCI Rec.): Liste 35
Denominaciones Comunes Internacionales Propuestas (DCI Rec.): Lista 35
(WHO Drug Information, Vol. 9, No. 3, 1995)

p 25 **teverelixum**
teverelix

replace the chemical name by the following:
N-acetyl-3-(2-naphthyl)-D-alanyl-*p*-chloro-D-phenylalanyl-3-(3-pyridyl)-D-alanyl-L-seryl-L-tyrosyl-N^6-carbamoyl-D-lysyl-L-leucyl-N^6-isopropyl-L-lysyl-L-prolyl-D-alaninamide

tévérélix	*remplacer le nom chimique par*
	[*N*-acétyl-3-(naphtalén-2-yl)-D-alanyl]-(4-chloro-D-phénylalanyl)-[3-(pyridin-3-yl)-D-alanyl]-L-séryl-L-tyrosyl-[N^6-(carbamoyl)-D-lysyl]-L-leucyl-[N^6-(1-méthyléthyl)-L-lysyl]-L-prolyl-D-alaninamide
teverelix	*sustituyase el nombre químico por*
	[*N*-acetil-3-(naftalen-2-il)-D-alanil]-(4-cloro-D-fenilalanil)-[3-(piridin-3-il)-D-alanil]-L-seril-L-tirosil-[N^6-(carbamoil)-D-lisil]-L-leucil-[N^6-(1-metiletil)-L-lisil]-L-prolil-D-alaninamida

Proposed International Nonproprietary Names (Rec. INN): List 38
Dénominations communes internationales proposées (DCI Rec.): Liste 38
Denominaciones Comunes Internacionales Propuestas (DCI Rec.): Liste 38
(WHO Drug Information, Vol. 11, No. 3, 1997)

p 162 **bimoclomolum**

bimoclomol	*replace the chemical name by the following*
	(±)-*N*-(2-hydroxy-3-piperidinopropoxy)nicotinimidoyl chloride

p 175 **opratonii iodidum**

opratonium iodide	*replace the chemical name by the following:*
	trimethyl[3-(10-undecenamido)propyl]ammonium iodide
ioduro de opratonio	*sustituyase el nombre químico por lo siguiente:*
	ioduro de trimetil[3-(10-undecenamido)propil]amonio

p 178 **tasonerminum**

tasonermin	*replace the graphic formula by the following.*
tasonermine	*remplacer la formule développée par la suivante:*
tasonermina	*sustituyase la fórmula desarrollada por la siguienta.*



Procedure and Guiding Principles / Procédure et Directives / Procedimientos y principios generales

The text of the *Procedures for the Selection of Recommended International Nonproprietary Names for Pharmaceutical Substances* and *General Principles for Guidance in Devising International Nonproprietary Names for Pharmaceutical Substances* will be reproduced in uneven numbers of proposed INN lists only

Les textes de la *Procédure à suivre en vue du choix de dénominations communes internationales recommandées pour les substances pharmaceutiques* et des *Directives générales pour la formation de dénominations communes internationales applicables aux substances pharmaceutiques* ont été publiés avec la liste 77 des DCI proposées et seront, à nouveau, publiés avec la prochaine liste.

El texto de los *Procedimientos de selección de denominaciones comunes internacionales recomendadas para las sus-tancias farmacéuticas* y de los *Principios generales de orientación para formar denominaciones comunes internacio-nales para sustancias farmacéuticas* aparece solamente en los números impares de las listas de DCI propuestas.